Encephalopathy
44
8
8
24
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.5%
2 terminated out of 44 trials
92.3%
+5.8% vs benchmark
7%
3 trials in Phase 3/4
13%
3 of 24 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 24 completed trials
Clinical Trials (44)
Healthy Little Eyes
Prospective Observational Multimodal Neuromonitoring in Adult NSICU Patients
Against Chikungunya Virus and Neonatal Infection
The Aim of the Present Study is to Determine Outcome Predictors in Children Who Were Diagnosed as Acute Disseminated Encephalomyelitis (ADEM).
Automating Delirium Severity in the ICU
CoMind Early Feasibility Study
Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy
Initiating Pediatric Palliative Care in ACT Group 4
Neuroimmunology Registry and Biobank
TIPS Plus Transvenous Obliteration for Gastric Varices
Cerebral Pulsatility Index Compared To Mean Arterial Blood Pressure Guided Protocol In Sepsis Induced Encephalopathy:
Erythropoietin for Neonatal Encephalopathy in LMIC (EMBRACE Trial)
Build a Decision Aid Tool to Help Emergency Intensive Care Specialists in the Context of Hypoxic Ischemic Encephalopathy
Neurocognitive Impairment in Patients With COVID-19
RCT for Intermittent Versus Continuous Propofol Sedation for Pediatric Brain and Spine MRI Studies
Clinical Utility of Pediatric Whole Exome Sequencing
eegCap Application in Paediatrics wiTh redUced GCS in REsus
Prevalence of Encephalopathy in Patients With Inflammatory Bowel Diseases
a Vigibase Pharmacovigilance Study of ENzalutamide Drug-induced neurotoxicitY
Neurocognitive Impairment in Pediatric Patients With Meningoencephalitis and Sepsis-associated Encephalopathy